학술논문
Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy.
Document Type
Academic Journal
Author
Flisiak R; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bialystok, Poland.; Zarębska-Michaluk D; Department of Infectious Diseases, Jan Kochanowski University, 25-369 Kielce, Poland.; Janczewska E; Department of Basic Medical Sciences, Faculty of Health Sciences in Bytom, Medical University of Silesia, 41-902 Bytom, Poland.; Łapiński T; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bialystok, Poland.; Rogalska M; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Bialystok, Poland.; Karpińska E; Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 70-204 Szczecin, Poland.; Mikuła T; Department of Infectious and Tropical Disease and Hepatology, Medical University of Warsaw, 02-091 Warsaw, Poland.; Bolewska B; Department of Infectious Diseases, Poznan University of Medical Sciences, 61-701 Poznan, Poland.; Białkowska J; Department of Infectious and Liver Diseases, Medical University of Lodz, 90-419 Lodz, Poland.; Flejscher-Stępniewska K; Department of Infectious Diseases, Liver Diseases and Immune Deficiencies, Wroclaw Medical University, 50-367 Wroclaw, Poland.; Tomasiewicz K; Department of Infectious Diseases and Hepatology, Medical University of Lublin, 20-059 Lublin, Poland.; Karwowska K; Department of Infectious Diseases and Hepatology, Collegium Medicum, Nicolaus Copernicus University, 87-030 Bydgoszcz, Poland.; Pazgan-Simon M; Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 50-367 Wroclaw, Poland.; Piekarska A; Department of Infectious Diseases and Hepatology, Medical University of Lodz, 90-419 Lodz, Poland.; Berak H; Daily Unit, Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, Poland.; Tronina O; Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.; Garlicki A; Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, 31-008 Krakow, Poland.; Jaroszewicz J; Department of Infectious Diseases and Hepatology, Medical University of Silesia, 40-055 Katowice, Poland.
Source
Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2072-6694
Abstract
(1) Background: Treatment of hepatitis C virus (HCV) infections with direct-acting antivirals (DAA) has demonstrated high efficacy and an excellent safety profile. The cured patients showed a sustained virological response and improved liver function, but also a continued risk of hepatocellular carcinoma (HCC) during the 2-3 years of follow-up after treatment; (2) Methods: A total of 192 patients out of 209 of the primary AMBER study were analyzed five years after treatment with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin. Results: We confirmed that HCV clearance after DAA treatment is stable regardless of baseline liver fibrosis. We found that sustained virologic response is associated with a gradual but significant reduction in liver stiffness over 5 years. Liver function improved during the first 2 years of follow-up and remained stable thereafter. The risk of death due to HCC as well as death due to HCV persists through 5 years of follow-up after successful DAA treatment. However, in non-cirrhotic patients, it appears to clear up 3 years after treatment; (3) Conclusions: Monitoring for more than 5 years after curing HCV infection is necessary to assess the long-term risk of possible development of HCC, especially in patients with cirrhosis of the liver.